[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.149.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 349
Citations 0
Observation
July 2016

Posaconazole Substitution for Voriconazole-Associated Phototoxic Effects

Author Affiliations
  • 1University of Miami Miller School of Medicine, Miami, Florida
  • 2Florida Atlantic University Internal Medicine Residency Program, Boca Raton
  • 3Dermatology Associates of the Palm Beaches Inc, Delray Beach, Florida
  • 4Dermatology Residency Program, Broward Health, Ft Lauderdale, Florida
JAMA Dermatol. 2016;152(7):839-841. doi:10.1001/jamadermatol.2016.0345

Voriconazole is used for long-term prophylaxis or treatment of fungal infections. Voriconazole-induced phototoxic effects and photocarcinogenesis is an independent risk factor for squamous cell carcinoma (SCC) development in organ transplant recipients.1 An alternative for patients at risk for cutaneous cancer has not been well studied. We describe a patient with voriconazole-induced photocarcinogenesis whose symptoms and tumor count improved after substitution with posaconazole.

First Page Preview View Large
First page PDF preview
First page PDF preview
×